S Rubio

ORCID: 0000-0002-5841-2142
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Liver Diseases and Immunity
  • Liver Disease Diagnosis and Treatment
  • Eosinophilic Esophagitis
  • Biosimilars and Bioanalytical Methods
  • Immunodeficiency and Autoimmune Disorders
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Gastrointestinal disorders and treatments
  • Tuberculosis Research and Epidemiology
  • Infectious Aortic and Vascular Conditions
  • Diagnosis and treatment of tuberculosis
  • Pregnancy and Medication Impact
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Sports Dynamics and Biomechanics
  • Abdominal Trauma and Injuries
  • Abdominal vascular conditions and treatments
  • Mast cells and histamine
  • Research on Leishmaniasis Studies
  • Sarcoma Diagnosis and Treatment
  • Melanoma and MAPK Pathways
  • Biomarkers in Disease Mechanisms
  • Cerebrospinal fluid and hydrocephalus
  • Stoma care and complications
  • Macrophage Migration Inhibitory Factor

Universidad Rey Juan Carlos
2025

Hasselt University
2024

Instituto de Investigación Biomédica de Salamanca
2024

Centro de Investigación Biomédica en Red de Cáncer
2024

Navarre Institute of Health Research
2019-2023

Complejo Hospitalario de Navarra
2019-2022

Hospital Universitario de La Princesa
2004-2019

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2019

Universidad Autónoma de Madrid
2006-2019

Universidad de Navarra
2014

To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] real life.Patients from prospectively maintained ENEIDA registry treated with due to active UC were included. Clinical activity defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, 16.A total 113 patients They exposed for a median time 44 weeks. Response remission Week 8 60% 31%, respectively. In multivariate analysis, higher PMS 4 (odds ratio [OR] = 0].2; 95%...

10.1093/ecco-jcc/jjaa145 article EN Journal of Crohn s and Colitis 2020-07-09

Summary Background Transient elastography is a novel and non‐invasive technique for the evaluation of fibrosis in chronic liver disease. Few studies that exist value efficacy transient elastography, mainly hepatitis C virus‐infected patients. Aim To evaluate effectiveness, objectivity, reproducibility safety this technique. Methods We included 103 consecutive patients who underwent biopsy last 48 months with wide spectrum diseases. Median stiffness (expressed as kilopascals – kPa) was kept...

10.1111/j.1365-2036.2006.02999.x article EN Alimentary Pharmacology & Therapeutics 2006-07-12

Objectives. Our objective was to evaluate the efficacy and tolerability of bosentan in patients with systemic sclerosis (SSc) who develop ulcers healed ulcers. We also wanted analyse effect on other skin general outcome measurements. Methods. In present prospective, observational, non-controlled study, we followed all SSc started treatment for ischaemic from January 2003 June 2006 our centre. recorded measurements at baseline 6 months. Results. Fifteen were included. After a median follow-up...

10.1093/rheumatology/ken001 article EN Lara D. Veeken 2007-12-18

Summary Background and Aims Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was compare treatment persistence, clinical efficacy, safety in inflammatory bowel disease patients who maintained vs. those switched biosimilar. Methods Patients receiving were remission at standard dose of included. formed non‐switch cohort (NSC), different biosimilars constituted switch (SC). Clinical defined as a Harvey–Bradshaw index ≤4 Crohn's partial...

10.1111/apt.17525 article EN Alimentary Pharmacology & Therapeutics 2023-04-23

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible damage long-term complications, reduced quality of life, invalidity, economic burden. Suboptimal control IBD is associated with higher healthcare resource utilization (HCRU), impaired life (QoL), work productivity. The IBD-PODCAST study aimed assess the proportion patients suboptimal its impact. a cross-sectional, multicenter characterize CD UC population optimal or...

10.1007/s10620-023-08220-9 article EN cc-by-nc Digestive Diseases and Sciences 2024-01-13

The aim of this study was to evaluate the effect an Athletic Performance Program (APP), implemented as a complement usual training routines professional football team, on match performance variables in players. APP designed target mobility, stability, strength, multidirectional and sprint skills, which are critical for during competitive matches. A prospective quasi-experimental conducted over three consecutive seasons. Fifty-four players were randomly allocated into control group (CG, n =...

10.3389/fspor.2024.1496895 article EN cc-by Frontiers in Sports and Active Living 2025-01-08

Abstract Background Risankizumab (RSK) is the first anti-IL-23 drug approved in 2022 for moderate-to-severe Crohn’s disease (CD). Data on its real-world effectiveness and safety remain limited. This study assesses short- mid-term of RSK profile a clinical practice setting. Methods A retrospective analysis was conducted patients with refractory luminal CD treated at our tertiary centre between March July 2024 who completed induction therapy. The primary endpoint remission weeks 12 24,...

10.1093/ecco-jcc/jjae190.1289 article EN Journal of Crohn s and Colitis 2025-01-01
Ana Vázquez Andrea Núñez Ortiz S Rubio María Teresa Diz-Lois Palomares Sabino Riestra and 95 more Horacio Alonso‐Galán E Fernández-Salgado R Ferreiro-Iglesias Milagros Vela Ángel Ponferrada Díaz Eugenia Sánchez Rodríguez Vicent Hernández Lara Arias Jesús Barrio José María Huguet Daniel Ginard Montserrat Rivero Isabel Vera Mendoza Inmaculada Alonso-Abreu J M Benítez Mariam Aguas Iago Rodríguez–Lago Xavier Calvet Luis Fernández‐Salazar Ana Echarri M Arroyo Mercè Navarro‐Llavat Pablo Vega Mónica Sierra Elena Guerra del Río Raquel Vicente María José Casanova Pablo Navarro Jone Ortiz de Zárate Pilar Varela Trastoy Kateřina Špičáková Ana Gutiérrez María Dolores Martín‐Arranz Concepción Piñero Álvaro Hernández-Martínez Emilio Torrella Cortés José Miguel Marrero R H Lorente Poyatos Lidia Martí Romero Orencio Bosch José María Duque Montserrat Aceituno H Fernández Belén Crespo Suarez Ana Fuentes Coronel Liliana Pozzati Pilar Robledo Eva Sesé Abizanda Belén Herreros Martínez Nuria Jiménez Pilar López Serrano Manuela Josefa Sampedro Fernando Bermejo Alfredo J. Lucendo Margarita Muñoz Vicente Margarita Menacho José Joaquín Ramírez Palanca Raquel Camargo Amalia Carmona Sandra Torrá Alsina Margalida Calafat José Luis Fernández Forcelledo Juan Nerín de la Puerta Isabel Nicolás Verónica Opio Yolanda Ber Abdel Bouhmidi A. Abraldes Bechiarelli Carlos Castańo-Milla Noelia Cruz Jordi Gordillo Amparo Sapiña Alina López Silvia Rodríguez Mondéjar María Teresa Novella Durán Belén Botella Marcos Kutz Lilyan Kolle Ignacio Marín‐Jiménez Francisco J. Martínez-Cerezo Rebeca Irisarri Eduardo Iyo Óscar Roncero M Sàbat Yolanda Torres Domínguez César Ledezma Eva María Zapata María José Fernández Alcalá Laia Lluis Cristina Martínez Pascual Isabel Blázquez Gómez Luis Hernández Laura Mata Ana Monrobel Alejandro Hernández-Camba

10.1016/s0210-5705(25)00148-7 article ES Gastroenterología y Hepatología 2025-01-01

Aim It has been suggested that patients with porphyria cutanea tarda (PCT) are at high risk of developing hepatocellular carcinoma (HCC); however, this not confirmed by other workers. The aim our study was to evaluate the incidence HCC in PCT, and assess possible co-factors associated cancer development. Methods Thirty-nine consecutive a diagnosis PCT were included. Hepatitis B virus hepatitis C (HCV) infection investigated, percutaneous liver biopsy performed. Patients treated phlebotomies,...

10.1097/01.meg.0000108318.52416.c9 article EN European Journal of Gastroenterology & Hepatology 2004-07-01

Aim: To evaluate outcomes of early dose optimization golimumab in ulcerative colitis (UC) patients with inadequate response to induction treatment. Methods: This observational, multicenter, cohort study included moderate-to-severe active UC and subcutaneous doses, whom weight-based maintenance (European labeling) 50 mg every 4 weeks (q4wk) was optimized before week 14 100 q4wk. At 14, we assessed clinical remission using the partial Mayo score. In long term cumulative probabilities...

10.1080/03007995.2019.1579557 article EN Current Medical Research and Opinion 2019-02-06

Figure 1 A 72-year-old man was referred to our hospital with fever and melena. He had undergone surgery 14 months previously for treatment of an infrarenal aortic aneurysm, the insertion a bifurcated endoprosthesis, as seen on this plain abdominal radiograph.

10.1055/s-2003-41511 article EN Endoscopy 2003-08-01

Small bowel capsule endoscopy (SBCE) is a noninvasive method to detect endoscopic postoperative recurrence (POR) after an ileocolonic resection in Crohn's Disease (CD). Few studies have evaluated the role of SBCE early POR (= 12 months). Data for detection late (>12 months) and evaluation treatment response previous scarce. We aimed assess performance three scenarios (early-POR, late-POR, previous-POR).Retrospective 11-year cohort study procedures performed on CD patients with resection....

10.51821/85.3.10535 article EN Acta Gastro Enterologica Belgica 2022-09-01

Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) real life. Methods Patients from prospectively maintained ENEIDA registry treated with due active UC were included. Clinical activity defined based on Partial Mayo Score (PMS). The short-term response assessed at week 4, 8 16. last-observation-carried-forward method used patients that stopped before time-points for clinical assessment. Variables associated remission identified...

10.1093/ecco-jcc/jjz203.028 article EN Journal of Crohn s and Colitis 2020-01-01
Coming Soon ...